ALPS Advisors’s Celldex Therapeutics CLDX Stock Holding History
Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $729K | Sell |
35,812
-14,126
| -28% | -$287K | ﹤0.01% | 579 |
|
2025
Q1 | $906K | Sell |
49,938
-3,712
| -7% | -$67.4K | 0.01% | 485 |
|
2024
Q4 | $1.36M | Buy |
53,650
+2,993
| +6% | +$75.6K | 0.01% | 410 |
|
2024
Q3 | $1.72M | Sell |
50,657
-742
| -1% | -$25.2K | 0.01% | 383 |
|
2024
Q2 | $1.9M | Buy |
51,399
+5,959
| +13% | +$221K | 0.01% | 346 |
|
2024
Q1 | $1.91M | Buy |
45,440
+7,795
| +21% | +$327K | 0.01% | 359 |
|
2023
Q4 | $1.49M | Buy |
37,645
+2,797
| +8% | +$111K | 0.01% | 383 |
|
2023
Q3 | $959K | Buy |
34,848
+113
| +0.3% | +$3.11K | 0.01% | 465 |
|
2023
Q2 | $1.18M | Buy |
34,735
+3,630
| +12% | +$123K | 0.01% | 437 |
|
2023
Q1 | $1.12M | Sell |
31,105
-844
| -3% | -$30.4K | 0.01% | 446 |
|
2022
Q4 | $1.42M | Buy |
31,949
+6,389
| +25% | +$285K | 0.01% | 368 |
|
2022
Q3 | $718K | Sell |
25,560
-2,180
| -8% | -$61.2K | 0.01% | 536 |
|
2022
Q2 | $748K | Buy |
+27,740
| New | +$748K | 0.01% | 517 |
|
2021
Q2 | – | Sell |
-71,581
| Closed | -$1.48M | – | 906 |
|
2021
Q1 | $1.48M | Buy |
71,581
+861
| +1% | +$17.7K | 0.01% | 353 |
|
2020
Q4 | $1.24M | Buy |
+70,720
| New | +$1.24M | 0.01% | 366 |
|
2017
Q2 | – | Sell |
-7,013
| Closed | -$380K | – | 773 |
|
2017
Q1 | $380K | Buy |
7,013
+526
| +8% | +$28.5K | ﹤0.01% | 671 |
|
2016
Q4 | $344K | Sell |
6,487
-2,058
| -24% | -$109K | ﹤0.01% | 655 |
|
2016
Q3 | $518K | Sell |
8,545
-700
| -8% | -$42.4K | ﹤0.01% | 265 |
|
2016
Q2 | $609K | Buy |
9,245
+1,845
| +25% | +$122K | 0.01% | 229 |
|
2016
Q1 | $420K | Sell |
7,400
-1,263
| -15% | -$71.7K | ﹤0.01% | 531 |
|
2015
Q4 | $2.04M | Sell |
8,663
-1,613
| -16% | -$379K | 0.02% | 177 |
|
2015
Q3 | $16.2K | Buy |
10,276
+3,761
| +58% | +$5.95K | 0.02% | 183 |
|
2015
Q2 | $2.47M | Buy |
6,515
+3,305
| +103% | +$1.25M | 0.02% | 152 |
|
2015
Q1 | $1.34M | Buy |
+3,210
| New | +$1.34M | 0.01% | 170 |
|